ATE387459T1 - Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie - Google Patents

Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie

Info

Publication number
ATE387459T1
ATE387459T1 AT01926716T AT01926716T ATE387459T1 AT E387459 T1 ATE387459 T1 AT E387459T1 AT 01926716 T AT01926716 T AT 01926716T AT 01926716 T AT01926716 T AT 01926716T AT E387459 T1 ATE387459 T1 AT E387459T1
Authority
AT
Austria
Prior art keywords
methods
compounds
lowering cholesterol
cholesterol levels
inducing hypertriglyceridemia
Prior art date
Application number
AT01926716T
Other languages
English (en)
Inventor
Vassilis Zannis
Kyriakos Kypreos
Original Assignee
Kos Pharma Inc
Univ Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/827,854 external-priority patent/US20020123093A1/en
Application filed by Kos Pharma Inc, Univ Boston filed Critical Kos Pharma Inc
Application granted granted Critical
Publication of ATE387459T1 publication Critical patent/ATE387459T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775Apolipopeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT01926716T 2000-04-06 2001-04-06 Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie ATE387459T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54438600A 2000-04-06 2000-04-06
US67908800A 2000-10-04 2000-10-04
US09/827,854 US20020123093A1 (en) 2000-04-06 2001-04-05 Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia

Publications (1)

Publication Number Publication Date
ATE387459T1 true ATE387459T1 (de) 2008-03-15

Family

ID=27415432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01926716T ATE387459T1 (de) 2000-04-06 2001-04-06 Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie

Country Status (9)

Country Link
US (1) US20060142200A1 (de)
EP (1) EP1274717B1 (de)
JP (1) JP2003530835A (de)
AT (1) ATE387459T1 (de)
AU (2) AU2001253233B2 (de)
CA (1) CA2405870A1 (de)
MX (1) MXPA02009804A (de)
NO (1) NO20024769L (de)
WO (1) WO2001077136A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675072A (zh) * 2006-12-13 2010-03-17 加利福尼亚大学董事会 胆固醇流出的有效和选择性的介质
EP3191578B1 (de) * 2014-09-12 2020-11-04 Whitehead Institute for Biomedical Research Zellen zur expression von apolipoprotein e und verwendungen davon
KR102700963B1 (ko) 2017-10-03 2024-09-02 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
WO2019070891A1 (en) 2017-10-03 2019-04-11 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISORDERS
WO2020112802A1 (en) * 2018-11-28 2020-06-04 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative disease
KR20230112672A (ko) * 2020-11-25 2023-07-27 프리베일 테라퓨틱스, 인크. 신경변성 질환을 위한 유전자 요법
WO2025144884A1 (en) * 2023-12-26 2025-07-03 Kisbee Therapeutics, Inc. Apoe lipoprotein mimetics and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2145535C (en) * 1992-09-25 2007-07-17 Axel Kahn Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
AU7019494A (en) * 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5811243A (en) * 1993-08-31 1998-09-22 Duke University Methods and compositions for binding tau and MAP2c proteins
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease

Also Published As

Publication number Publication date
WO2001077136A1 (en) 2001-10-18
AU2001253233B2 (en) 2006-12-07
EP1274717A1 (de) 2003-01-15
EP1274717B1 (de) 2008-02-27
NO20024769D0 (no) 2002-10-03
MXPA02009804A (es) 2003-07-14
AU5323301A (en) 2001-10-23
JP2003530835A (ja) 2003-10-21
EP1274717A4 (de) 2004-07-14
NO20024769L (no) 2002-11-26
CA2405870A1 (en) 2001-10-18
US20060142200A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
EA200501772A1 (ru) Способы измерения экспрессии генов из фиксированного и залитого в парафин образца ткани
DE69936948D1 (de) Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
EP1254267A4 (de) Zusammensetzungen und methoden zur früherkennung von eierstockkrebs
DK1261360T3 (da) Casein-afledte peptider og anvendelser deraf i behandling
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
EP1322307A4 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
DE602004020999D1 (de) Materialien und verfahren zum einfangen von krankheitserregern und zur abtrennung von aurintricarbonsäure aus einer probe
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
ATE387459T1 (de) Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie
ATE346147T1 (de) Zusammensetzungen und methoden zur wundheilung
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE602004005821D1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE333887T1 (de) Verfahren zur behandlung von instabiler angina pectoris
ATE479705T1 (de) Reduzierter slam abhängiger zell eintritt
DE602004001047D1 (de) Phospholipidester von Clofarabin
DE60132986D1 (de) Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie
DK1339737T3 (da) Immunomodulatorisk protein dannet ud fra Yaba-abetumorvirus
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
EP1359910A4 (de) Methode zur behandlung von glaukom ii b
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties